enVVeno Medical Corp 8-K

What Happened

• On April 29, 2026, enVVeno Medical Corporation (NVNO) announced via Form 8-K and a press release that the U.S. Food & Drug Administration approved the company’s Investigational Device Exemption (IDE) for the Transcatheter Venous Valve Endoprosthesis (TAVVE®) pivotal study. The IDE authorization allows enVVeno to begin a U.S. clinical pivotal trial of its minimally invasive enVVe® System for severe chronic venous insufficiency (CVI).
• The filing also notes the company’s reported cash and investments of approximately $25 million as of March 31, 2026 (Item 2.02) and that the press release was furnished as Exhibit 99.1.

Key Details

• Study design: Stage 1 will enroll 10 patients and submit 30-day safety results to the FDA; those 10 remain a separate cohort. Stage 2 will enroll 220 patients (165 receiving enVVe valve; 55 randomized to a control arm receiving standard care).
• Timeline and scale: The second stage begins after the FDA review of the initial 30-day safety data; study may enroll at up to 40 U.S. clinical sites. One year after the 220th patient in stage 2 is enrolled, enVVeno would be eligible to file for FDA post‑marketing approval.
• Device highlights: enVVe System is a minimally invasive, self‑expanding venous valve (3 sizes), mono‑cusp porcine pericardium leaflet, 13 Fr crimped delivery profile, and delivered via an over‑the‑wire coaxial pull system.
• Cash runway: Approximately $25 million in cash and investments as of March 31, 2026, which the company expects will fund operations into the third quarter of 2027.

Why It Matters

• FDA IDE approval is a material regulatory milestone that lets enVVeno start its pivotal U.S. trial — a required step toward potential FDA post‑market approval and commercial access for a non‑surgical venous valve.
• The staged trial design (initial 10‑patient safety cohort followed by a randomized 220‑patient cohort) sets clear near‑term milestones investors can track: enrollment progress and the initial 30‑day safety readout, then larger efficacy/safety data from the randomized cohort.
• The reported ~$25M cash balance gives a view of near‑term funding; the company expects this to fund operations into Q3 2027, so investors should watch trial costs, enrollment pace, and any future financing needs.